Video

Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer

Author(s):

Rahul Aggarwal, MD

In Partnership With:

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Studies have shown that early application of these potent therapies demonstrates benefit. There is a lot of ongoing drug development for high-risk patients who do not respond well to ADT or whose prostate-specific antigens do not decline fast enough after induction hormone therapy, says Aggarwal.

The impact of the early use of these therapies on the time to progression remains to be seen. The question also arises of how to treat more aggressive cancer for patients who are castration resistant, had their androgen receptor pathway suppressed, or have already been treated with abiraterone acetate (Zytiga), enzalutamide (Xtandi), or apalutamide.

Related Videos
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami
Related Content
The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Matthew R. Cooperberg, MD, MPH, of UCSF
July 18th 2024

Prostate Cancer Test Is Missing Early Disease in Transgender Women

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
July 11th 2024

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer